Resolution Therapeutics to Host Virtual R&D Webinar on Liver Disease with World Leading Hepatologist Arun Sanyal, M.D.

Resolution Therapeutics United Kingdom United States of America

or register using this link.

About Resolution Therapeutics

Resolution Therapeutics is a clinical-stage biopharmaceutical company pioneering macrophage cell therapy for transformative outcomes in inflammatory organ diseases. The Company leverages its proprietary platform to engineer autologous macrophages with distinct pro-regenerative properties as cell therapy medicines capable of delivering superior patient outcomes across the spectrum of inflammatory organ disease. Resolution's initial focus is on developing RTX001, its lead product candidate with first-in-class potential supported by preclinical data demonstrating anti-fibrotic and anti-inflammatory advantages relative to non-engineered macrophages, for patients diagnosed with end-stage liver disease. The Company is also advancing efforts to expand the potential of its platform beyond the liver into indications where engineered macrophages have therapeutic potential. Resolution Therapeutics is based in Edinburgh and London. Learn more by visiting https://resolution-tx.com/ and engage with us on LinkedIn.

 

View original content:https://www.prnewswire.co.uk/news-releases/resolution-therapeutics-to-host-virtual-rd-webinar-on-liver-disease-with-world-leading-hepatologist-arun-sanyal-md-302172002.html